Ravulizumab - Atypical haemolytic uraemic syndrome
You are here : Home > Formulary Search > Ravulizumab - Atypical haemolytic uraemic syndrome
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Red
Formulations :
No records returned.
Formulary Status :
Associated Icons :
R
SPC
Restrictions / Comments :
Important
Not on Surrey Heartlands Trust formularies. Trusts with renal centres (locally this is Epsom, Frimley & Brighton) will retain prescribing responsibility’.
Documents :
NICE Technology Appraisal
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Ravulizumab
Indication :
Atypical haemolytic uraemic syndrome
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Committee Recommendations (1)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.
Other Indications
Below are listed other indications that Ravulizumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Atypical haemolytic uraemic syndrome.